25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 25 of 25 clinical reviews.
A physician-reviewed, evidence-based guide to using romosozumab (Evenity) in patients with severe osteoporosis after bariatric surgery, covering pharmacokinetics, dosing, calcium repletion, and transition strategies.
A clinical review of whether romosozumab (Evenity) causes appetite or cravings changes, what the trial data show, and how to counsel patients starting this osteoporosis therapy.
A clinical review of romosozumab use in patients with autoimmune conditions, covering immunogenicity, drug interactions, cardiovascular signals, and dosing guidance for rheumatologists and endocrinologists.
A physician-level review of romosozumab's mechanism, BMD gains, fracture-reduction data from ARCH and FRAME, cardiovascular risk, and clinical sequencing strategy for severe osteoporosis.
A MD/PharmD-level review of the cancer risk signal associated with romosozumab (Evenity), including ARCH trial data, FDA label language, post-marketing surveillance findings, and clinical decision frameworks for prescribers.
A detailed clinical review of romosozumab (Evenity) cardiovascular risk, including ARCH trial data, FDA black box warning, post-marketing evidence, and patient selection guidance for severe osteoporosis treatment.
A physician-reviewed, primary-literature analysis of whether romosozumab (Evenity) affects cognitive function, including sclerostin biology, available trial data, and what patients with osteoporosis should know before starting therapy.
A physician-reviewed comparison of branded Evenity (romosozumab) and compounded romosozumab, covering clinical trial data, regulatory status, safety, dosing, and who qualifies for each option.
A GRADE-level review of romosozumab (Evenity) clinical trials, fracture-reduction data, cardiovascular safety, and guideline recommendations for severe osteoporosis management.
A clinical deep-dive into romosozumab (Evenity) hair loss and skin changes, covering trial data, proposed mechanisms, management strategies, and FDA labeling.
A clinical deep-dive into romosozumab's effect on liver function tests, hepatotoxicity risk, ALT/AST monitoring, and how ARCH trial data and FDA labeling inform prescribing decisions.
A clinical deep-dive into whether romosozumab (Evenity) affects mood, depression, anxiety, or cognition, with primary-literature citations, FDA safety data, and a practical prescribing framework.
A clinical deep-dive into how romosozumab (Evenity) affects bone metabolism, energy expenditure, and systemic physiology, with primary-literature citations and dosing guidance.
A clinician-level review of romosozumab (Evenity) standard dosing, the complete absence of validated microdosing protocols, fracture-risk evidence from ARCH and FRAME, and what physicians should know before considering any off-label dose modification.
A clinical deep-dive into how romosozumab (Evenity) affects skeletal muscle, which muscle-preservation strategies pair best with its 12-month anabolic window, and what the evidence says about concurrent resistance training, protein intake, and adjunct therapies.
A clinician-level guide to diagnosing and managing romosozumab plateau and non-response in severe osteoporosis, with primary-literature citations, dosing protocols, and sequential therapy strategies.
A physician-level guide to the romosozumab pre-surgery hold window, covering ARCH trial data, cardiovascular risk, timing protocols, and return-to-therapy decisions after orthopedic or elective surgery.
What happens to bone density and fracture risk when romosozumab (Evenity) is stopped? A clinical deep-dive covering the anabolic window, rebound bone loss, and the mandatory antiresorptive follow-on therapy backed by ARCH and FRAME trial data.
Does romosozumab (Evenity) protect the kidneys or put them at risk? A physician-reviewed deep dive into ARCH trial data, sclerostin biology, phosphate handling, and dosing guidance for patients with CKD.
A clinical deep-dive into how season, temperature, sun exposure, vitamin D status, and patient scheduling affect romosozumab (Evenity) therapy for severe osteoporosis. Written for prescribers and informed patients.
A clinician-reviewed deep dive into whether romosozumab (Evenity) affects sexual function, libido, and hormone levels, with primary-literature citations and a practical prescribing framework.
A physician-reviewed deep dive into how romosozumab (Evenity) may affect sleep architecture, with primary-literature citations, dose details, and clinical guidance for prescribers and patients.
A clinician-level guide to managing romosozumab (Evenity) injections around travel, timezone changes, and missed-dose windows, with primary-literature citations and practical scheduling frameworks.
A physician-reviewed, week-by-week guide to romosozumab (Evenity) during your first month of treatment: injection procedure, early bone-turnover shifts, side effects, and what your prescriber monitors.
Board-reviewed guidance on when and how to restart romosozumab (Evenity) after an acute illness interrupts therapy, with primary-literature citations, dosing timelines, and cardiovascular risk reassessment.